CPBIO Holding Co (HKSE:03839) Notes Receivable: HK$0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:03839 CPBIO Holding Co Ltd HKSE:03839
71 GF Score
Price HK$8.71
GF Value HK$3.78
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is CPBIO Holding Co Notes Receivable?

CPBIO Holding Co HKSE:03839 71 Notes Receivable is HK$0 Mil as of Mar. 2026. GuruFocus rates HKSE:03839 with a GF Score™ of 71/100 and a GF Value™ of HK$3.78 (Significantly Overvalued). The stock has 5 warning signs investors should review.

CPBIO Holding Co's Notes Receivable for the quarter that ended in Mar. 2026 was HK$0 Mil.

CPBIO Holding Co Notes Receivable Related Terms

CPBIO Holding Co Notes Receivable Historical Data

* Premium members only.

The historical data trend for CPBIO Holding Co's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CPBIO Holding Co Notes Receivable Chart

CPBIO Holding Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CPBIO Holding Co Quarterly Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
HKSE:03839
71GF Score
CPBIO Holding Co Ltd HKSE:03839
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CPBIO Holding Co Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of HK$0 Mil mean?
CPBIO Holding Co (HKSE:03839) has a Notes Receivable of HK$0 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on CPBIO Holding Co and its competitors.
Is CPBIO Holding Co's Notes Receivable too high?
CPBIO Holding Co's current Notes Receivable is HK$0 Mil. Overall, CPBIO Holding Co has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CPBIO Holding Co's Notes Receivable compare to ZTS?
CPBIO Holding Co's Notes Receivable of HK$0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Drug Manufacturers company?
A good Notes Receivable depends on the Drug Manufacturers industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on CPBIO Holding Co and its competitors. CPBIO Holding Co's current Notes Receivable is HK$0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CPBIO Holding Co stock overvalued right now?
Based on GuruFocus' analysis, CPBIO Holding Co (HKSE:03839) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$3.78, compared to a current price of HK$8.71 — trading 130.4% above its estimated fair value. The current Notes Receivable is HK$0 Mil. CPBIO Holding Co's overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For CPBIO Holding Co (HKSE:03839), the current Notes Receivable is HK$0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CPBIO Holding Co (HKSE:03839) Overvalued in 2026?

Based on GuruFocus' analysis, CPBIO Holding Co stock appears to be overvalued. The current stock price of HK$8.71 is trading 130.4% above its estimated GF Value™ of HK$3.78. GuruFocus considers CPBIO Holding Co to be Significantly Overvalued.

Key valuation signals for HKSE:03839:

  • Notes Receivable: HK$0 Mil
  • GF Value™: HK$3.78 vs. price of HK$8.71 (130.4% above fair value)
  • GF Score™: 71/100 with 5 warning signs

No single metric tells the full story. See the HKSE:03839 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CPBIO Holding Co Business Description

Other Exchanges CAIHF:USA
Address 16 Harcourt Road, 21st Floor, Far East Finance Centre, Central, Hong Kong, HKG
Chia Tai Enterprises International Ltd is engaged in the manufacture and sale of animal health products and chlortetracycline (CTC). The group has two reportable segments: Biotech Business and Investment Business. The Biotech Business segment is involved in the manufacture and/or sale of animal health products and chlortetracycline. The Investment Business segment is engaged in the trading of machinery and the manufacture and sale of automotive parts through the group's joint ventures and associates. It generates the majority of its revenue from the Biotech Business segment. Its geographical segments are Mainland China, which generates key revenue, Asia Pacific (excluding mainland China), the Americas, Europe, and Others.
71GF Score

Get the complete analysis for HKSE:03839

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$8.71
Price
HK$3.78
GF Value